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A B S T R A C T
Reducing preterm birth is a priority for Maternity and Children’s services. In the recent UK Department of
Health publication ‘Safer Maternity Care’ the Secretary of State for Health aimed to achieve the national
maternity safety ambition by pledging to reduce the rate of preterm birth from 8% to 6%. It was proposed
that specialist preterm birth services should be established in the UK in order to achieve this aim. In
response the Preterm Clinical Network has written Commissioning Guidance aimed to establish best
practice pathways and agreed models of care to reduce variation nationally. They have been developed by
clinical experts in the ﬁeld, from within the UK, to provide recommendations for commissioning groups
and to recommend pathways to organisations with the aim of reducing the incidence of preterm birth.
Three key areas of care provision are focused on: prediction, prevention and preparation of women at
high risk of PTB. This Expert Opinion, will summarise the Commissioning Guidance.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Preterm birth (PTB), deﬁned as delivery at less than 37+0 weeks
gestation, is a common complication of pregnancy, comprising
around 8% of births in England and Wales [1]. It is the most important
singledeterminantofadverse infantoutcomewithregardstosurvival
and quality of life [2]. Babies born preterm have high rates of early,
late, and post-neonatal mortality and morbidity. PTB is estimated to
cost health services in England and Wales £3.4bn per year [1].
Reducing preterm birth is a priority for Maternity and Child-
ren’s services. In the recent Department of Health publication Safer
Maternity Care the Secretary of State for Health aimed to achieve
the national maternity safety ambition by pledging to reduce the
rate of preterm birth from 8% to 6%. He proposed that specialist
preterm birth services across the country could provide a
mechanism through which change could be focused and delivered
[3]. In response, the NHS England Saving Babies’ Lives Care Bundle
Element 5 is speciﬁc to preterm birth prevention and will reference
guidelines for commissioners and providers, which are summar-
ised in this commentary.
The guidelines also align with the NHS’ Long Term Plan which
emphasises the need to focus on pre-term mortality and preterm
birth prevention and supports the development of specialised
preterm birth services across the UK [4]. They aim to establish best
practice pathways and agreed models of care to reduce variation
nationally. They have been developed by clinical experts in the
ﬁeld, from the UK, to provide recommendations for commissioning
groups and to recommend pathways to organisations with the aim
of reducing the incidence of preterm birth.
Three key areas of care provision are focused on: prediction,
prevention and preparation of women at high risk of PTB. Sources
of funding and ways of evaluating implementation and perfor-
mance are also outlined.
Prevention
All acute maternity units should offer basic measures to identify
and manage the care of women at high risk of PTB, with specialised
input from more experienced practitioners within each Local
Maternity System to provide services such as high vaginal or
transabdominal cerclage. The NHS Long Term Plan supports the
development of specialist preterm birth clinics across England [4]
with a commitment to fully implement the Saving Babies Lives
Care Bundle in 2020. To this end implementation of the Care
Bundle has been included in the planning guidance and
incorporated into the standard contract for 2019/20.
Strategies to prevent PTB should include establishment of
standard care pathways for high-risk women, facilitation of access
to specialised care in every maternity unit, establishment of a
preterm birth network to encourage research and facilitation of
large datasets of patient information (with patient consent) to
improve management and treatment of high-risk women.
Identiﬁcation of at-risk women
Community care
Correct identiﬁcation of women at high risk of preterm birth
facilitates interventions which have been shown to be beneﬁcial
either in prolongation of pregnancy or in reducing subsequent
neonatal morbidity and mortality.At the booking visit women should be screened for factors
known to be associated with PTB e.g. smoking and substance use,
domestic violence, and urinary tract infection and appropriate
support/treatment given.
Low, intermediate, or high-risk care can then be offered as
outlined below. Referral criteria can be seen in Table 1.
Hospital-based care
There should be provision for designated preterm prevention
specialists (PPS) in every maternity unit to provide an outpatient
service within their antenatal clinic for women referred for
screening. This should be able to accurately quantify risk using
transvaginal ultrasound measurement of cervical length (CL) and
appropriate predictive biomarkers such as quantitative ﬁbronectin
(qfFN) for asymptomatic high-risk women and provide timely
interventions for preterm birth prevention (such as cerclage,
progesterone, pessary).
Preterm prevention teams in more experienced units should be
contacted to assess women with complex obstetric and medical
histories, and have the facilities to provide high vaginal and
transabdominal cerclage where appropriate.
Ultrasound cervical length screening should be performed as a
minimum at 16 and 22 weeks in women identiﬁed at high risk,
and outside of this window and/or more frequently where
indicated. Those at intermediate risk should have at least one CL
assessment between 18 and 22 weeks, with referral to the local
PPS team if the CL is <25 mm. If the CL is  25 mm they may
return to a low-risk pathway. In asymptomatic women there is
usually no need to routinely carry out CL assessments beyond 26
weeks.
Cervicovaginal quantitative fetal ﬁbronectin may be used in
high risk asymptomatic women from 18 weeks gestation [5].
Preterm surveillance clinics have been shown to have signiﬁcant
ability in triaging women at high risk of preterm delivery [6].
Prevention
Several interventions have been assessed for women at high
risk of preterm birth: cervical cerclage, progesterone and pessaries.
Precisely in which women, and in what circumstances, each is
most helpful is not clear but are currently being investigated in
randomized control trials such as the SUPPORT study which is
comparing the three techniques [7].
Cervical cerclage
Women with a history of recurrent spontaneous preterm birth
or late miscarriage (16–34 weeks) may be offered a history-
indicated cervical cerclage. Transvaginal CL scan assessment of the
cervix within the second trimester can be recommended as an
alternative and is suitable for most women who have had a single
episode [8]. History-indicated cerclages should be placed by the
end of the ﬁrst trimester where possible.
In women who have had a failed transvaginal cerclage with
delivery or preterm premature rupture of membranes (PPROM)
before 28 weeks of gestation, a transabdominal cerclage may be
considered [9]. Placement may be pre-conception but can be
performed during pregnancy (<14 weeks). All Trusts should
identify two or three clinicians to specialise in transvaginal
cervical cerclage to enable sufﬁcient capacity for 52-week cover.
Table 1
Risk factors associated with preterm birth and recommended referral pathways for preterm prevention surveillance.
Risk factor Pathway
High risk
 Previous preterm birth or mid-trimester loss (16 to 34 weeks gestation)
 Previous preterm prelabour rupture of membranes <34/40
 Previous use of cervical cerclage
 Known uterine variant (i.e. unicornuate, bicornuate uterus or uterine septum)
 Intrauterine adhesions (Ashermann’s syndrome)
 History of trachelectomy (for cervical cancer)
Surveillance
1 Referral to local or tertiary Preterm Prevention (PP) service by 12 weeks.
2 Further risk assessment based on history +/- examination as appropriate in
secondary care with identiﬁcation of women needing referral to tertiary
services.
3 All women to be offered transvaginal cervix scanning as a secondary screening
test to more accurately quantify risk at least twice (usually 2-4 weekly) between
16 and 24 weeks.
4 Additional use of quantitative fetal ﬁbronectin in asymptomatic women may be
considered where centres have this expertise.
Management
5 Interventions should be offered to women as appropriate, based on either
history or additional screening tests by clinicians able to discuss the relevant
risks and beneﬁts according to up to date evidence and relevant guidance, for
example Preterm Clinical Network guidance and NICE guidance. These
interventions should include cervical cerclage, pessary and progesterone as
appropriate.
Intermediate risk
 Previous delivery by caesarean section at full dilatation
 History of signiﬁcant cervical excisional event i.e. LLETZ where >10 mm depth
removed, or >1 LLETZ procedure carried out or cone biopsy (knife or laser,
typically carried out under general anaesthetic)
Surveillance
1) Refer to preterm birth prevention service by 12 weeks.
2) Further risk assessment based on history +/- examination as appropriate in
secondary care with discussion of the option of additional screening tests,
including:
a) A single transvaginal cervix scan between 18-22 weeks as a minimum.
b) Additional use of quantitative fetal ﬁbronectin in asymptomatic women can
be considered where centres have this expertise
Management
1) Interventions should be discussed with women as appropriate based on either
history or additional screening tests by clinicians able to discuss the relevant
risks and beneﬁts according to up to date evidence and relevant guidance. These
interventions should include cervical cerclage, pessary and progesterone as
appropriate.
2) Women at intermediate risk should be reassessed at 24 weeks for consideration
of transfer back to a low risk pathway.
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As an alternative to prophylactic cervical cerclage, women who
have had a history of spontaneous preterm birth or mid-trimester loss
between 16 + 0 and 34 + 0 weeks of pregnancy and in whom CL
<25 mm may be offered prophylactic progesterone [1]. It may also be
offeredwhen theCL<25 mmbetween 16 + 0and26 + 0inwomenwith
no history of spontaneous preterm birth or midtrimester loss [1].
Pessary
Arabin pessaries have been also used as an alternative to
prophylactic cervical cerclage or progesterone in women who have
had a history of spontaneous preterm birth or mid-trimester loss
between 16 + 0 and 34 + 0 weeks with a cervix <25 mm. As with the
other preventive modalities ongoing studies will help deﬁne which
women will most beneﬁt from pessary use.
Preparation
Symptomatic women should be assessed to stratify risk of those
at risk of imminent delivery to appropriately implement inter-
ventions to reduce neonatal morbidity and mortality.
Predictive tests can be used in accordance with NICE guidance [1]
where the woman is suspected to be in preterm labour and is >30
weeks. These tests include ultrasound measurement of CL (when <
15 mm she is deemed to be at high risk of preterm birth) and use of
quantitative fetal ﬁbronectinwhere CL measurement isnot available.
Each of these tests has high negative predictive values related to
the low prevalence. The positive predictive value is lower butsufﬁcient to allow intervention. The role of quantitative testing and
its use in clinical care (in conjunction with the use of algorithms
deployed in the QUIPP app [10]) remains encouraging and may
assist individualised consultation with parents.
Following conﬁrmation of at-risk status, the following inter-
ventions are recommended:
Corticosteroids
Where PPROM has occurred, or when women in suspected or
established labour, corticosteroids should be considered from 23 + 0–
35 + 6 weeks gestation (and offered between 26 + 0 and 33 + 6) [1]. A
reduction in neonatal mortality, respiratory distress, intra-ventricular
haemorrhage and pulmonary complications is conferred.
The importance of timing and appropriate administration has
recently been highlighted. Even a single steroid dose is associated
with a reduction in birthweight in those infants who delivered
after one week of administration compared with placebo [11] and
unnecessary intervention should be avoided.
In the event of inappropriate administration (ie without
delivery <7 days) a further course of steroids can be considered
where the ﬁrst dose has been given early in gestation and delivery
has not occurred, as it results in a reduction in respiratory distress
syndrome compared with placebo.
Magnesium sulphate
Magnesium sulphate should be offered between 24 + 0 and 29 + 6
weeks to womenwho are in established labour as it will decrease the
risk of cerebral palsy [1]. Its use may also be considered up to 33 + 6
4 L. Story et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology: X 3 (2019) 100018weeks [12]. The PReCePT initiative is an AHSN-driven strategy
seeking to adopt best practice in this regard [13].
Tocolysis
The use of tocolysis is not recommended for women at risk of
imminent preterm birth to improve neonatal outcomes unless
short-term delay is desirable i.e. for in utero transfer. There is no
evidence that maintenance tocolysis is beneﬁcial.
In utero transfer
Transfer of a mother with her baby in utero ensures that she is in
the right facility to receive the appropriate obstetric and neonatal
care. There is a reduced incidence of intra-ventricular haemorrhage
in very low birthweight babies when transfer is in utero comparison
with ex utero, as well as lower neonatal mortality and costs [14].
It is now a prioritised NHS England recommendation for Local
Maternity Systems (LMS) to take action to ensure that all women
<27 weeks are delivered in centres with a neonatal intensive care
unit, and that LMS and corresponding Operational Delivery
Networks (ODN) have clear guidelines for antenatal transfer in
the event of impending delivery <27 weeks [15]
Post pregnancy care
Follow up pathways for all women who have undergone a
PTB < 34 weeks should be in place. A postnatal consultation by the
local obstetric team should be offered to enable debrieﬁng,
planning care for future pregnancies, including discussion about
optimizing health preconception through improvements in diet
and weight loss, stopping smoking and periconceptual folic acid
[16]. If there is recurrent PTB or a more complex history, referral to
a more experienced preterm prevention specialist is recom-
mended.
Placental histology, undertaken by a perinatal pathologist,
should be routine for all deliveries < 34 weeks gestation to assess
for signs of infection/inﬂammation or ischaemia/infarction and
other pathologies associated with placental insufﬁciency accord-
ing to the Amsterdam criteria [17].
Women with a history of extreme preterm birth (<28 weeks)
despite the placement of a transvaginal cervical cerclage should be
counselled about the option of placing an abdominal cervical
cerclage either before or during the next pregnancy, to reduce the
risk of PTB.
Funding considerations
Funding to improve prevention or optimise the management of
preterm birth exists within the current maternity payment
pathway. Women deemed to be at risk of preterm birth and
requiring specialist care access the intermediate rate tariff, £700
above the standard tariff. In a typical setting of a unit overseeing
5000 deliveries each year, around 400 women are likely to be
identiﬁed as being at-risk, and funds of between £25-30k thereby
available to provide the necessary infrastructure costs. Day case or
overnight surgical procedures for cerclage insertion can be covered
under early pregnancy/gynaecology tariffs.
From the national perspective, cost analyses show that if
preterm birth can be deferred by one week of gestation, annual
savings to the NHS of £994 million will be made [18].
Conclusions and recommendations
The standardisation of preterm birth services and establish-
ment of care pathways to identify and manage women at high riskof PTB is imperative to reduce the preterm birth rate in the UK and
its associated morbidity and mortality. It is hoped that the
implementation of these guidelines will result in a reduction of
this burden.
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